Selpercatinib

Back to search

Molecule Structure

Scientific Name

Selpercatinib

Description of the Drug

Selpercatinib is a RET receptor tyrosine kinase inhibitor for the treatment of RET-driven non-small cell lung cancer, medullary thyroid cancer, and thyroid cancer in appropriate patient populations.

Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB15685

Brand Name(s)

Retevmo

Company Owner(s)

Loxo Oncology Inc

Mechanism(s) Of Action

Target Name Target Type Action Type Target ChEMBL ID
Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET CHIMERIC PROTEIN INHIBITOR CHEMBL3430888
Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET CHIMERIC PROTEIN INHIBITOR CHEMBL3430904
Tyrosine-protein kinase receptor RET SINGLE PROTEIN INHIBITOR CHEMBL2041

Unichem Links

SureChEMBL SCHEMBL20071478
Human Metabolome Database HMDB0304865
DrugBank DB15685
PubChem 134436906
BindingDB 296429
DrugCentral 5393
ChemicalBook CB34805442
Guide to Pharmacology 10318
rxnorm SELPERCATINIB RETEVMO